Mosquirixs

ApprovedBiologic

KKamuzu University of Health Sciences

Mosquirixs is one of 21 biologic programs targeting Malaria. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

MalariaApproved

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

Mosquirixs

KKamuzu University of Health Sciences

Approved

1 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 8

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria1 trial

The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children

Not yet recruiting·KKamuzu University of Health Sciences·Phase 4·NCT06424002·5,400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mosquirixs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mosquirixs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mosquirixs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kamuzu University of Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: KKamuzu University of Health Sciences

Mosquirixs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria1 trial

References

Drug Info

Quick Facts

Related News